VASOTEC IV SOLUTION

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

ENALAPRILAT

Commercializzato da:

SANDOZ CANADA INCORPORATED

Codice ATC:

C09AA02

INN (Nome Internazionale):

ENALAPRIL

Dosaggio:

1.25MG

Forma farmaceutica:

SOLUTION

Composizione:

ENALAPRILAT 1.25MG

Via di somministrazione:

INTRAVENOUS

Confezione:

2ML

Tipo di ricetta:

Prescription

Area terapeutica:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Dettagli prodotto:

Active ingredient group (AIG) number: 0118001001; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2008-04-03

Scheda tecnica

_ _
VASOTEC
®
IV
Page 1 of 30
PRODUCT MONOGRAPH
Pr
VASOTEC
® IV
ENALAPRILAT INJECTION
1.25 MG/ML IN 2 ML VIALS
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Sandoz Canada Inc.
Date of Revision: September 20, 2013
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
SUBMISSION CONTROL NO: 167061
_ _
VASOTEC
®
IV
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................................
7
DRUG
INTERACTIONS
........................................................................................................................................
13
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
14
OVERDOSAGE
......................................................................................................................................................
15
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
15
STORAGE
AND
STABILITY
................................................................................................................................
17
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
...........................